AlphAIAlphAI — Financial news for AI agents
citybiz.coOCT 52 min read$GEHC

GE HealthCare to Acquire SOFIE Biosciences for $945 Million

GE HealthCare agreed to acquire SOFIE Biosciences for $945M in cash, expanding its U.S. radiopharmaceutical manufacturing. The deal, expected to close in 2027, adds 15 manufacturing sites and 21 cyclotrons. GE HealthCare anticipates low-double-digit revenue growth from SOFIE and accretion to earnings. SOFIE will continue serving existing customers, including competitors, and GE HealthCare plans to invest further in the network.

Original reporting
citybiz.co
Published Oct 5, 2026, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 2:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
GE HealthCare to Acquire SOFIE Biosciences for $945 Million — source image
Source · citybiz.co
Decision brief

The 30-second read

$GEHCBullishHigh
01

Why it matters

The acquisition is expected to be accretive to revenue growth, adjusted EBIT margin, and EPS in the first full year, positioning GEHC for higher utilization of PET manufacturing capacity.

02

Market read

A major M&A move in the radiopharma space that could shift competitive dynamics and drive growth for GEHC.

03

What to watch

Regulatory approvals and potential competition from other CMO providers may delay full revenue realization.

Relevance 9/10Novelty 9/10Timing: today

Background

GE HealthCare is expanding its pharmaceutical diagnostics segment with a strategic acquisition of a contract manufacturing specialist.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare announced a $945 million cash acquisition of SOFIE Biosciences, expanding its PET radiopharmaceutical manufacturing network.

Expected impact

likely upward pressure as investors price in revenue accretion and strategic expansion

Evidence & confidence

Large‑scale M&A in a high‑growth PET market; accretive to earnings and provides new contract manufacturing revenue.

Market effects

Sector

strengthens the radiopharmaceutical and medical imaging sector by adding U.S. manufacturing capacity.

Regional

U.S. healthcare and biotech markets gain a larger domestic PET production footprint.

Global

enhances GE HealthCare's global imaging value chain, potentially influencing worldwide PET tracer supply.

Counterpoint

What could challenge this read

The $945M cash outlay could strain GEHC's balance sheet and dilute cash reserves if integration costs exceed expectations.

Key entities

  • Company
    GE HealthCare

    U.S.-listed medical imaging and diagnostics firm (ticker GEHC).

  • Company
    SOFIE Biosciences

    U.S. contract manufacturer of PET radiopharmaceuticals.

Read at source← All news

StoryGE HealthCare agrees $945 million purchase of SOFIE Biosciences

Also covered by

6 outlets

Related articles

OCT 7
$GEHCHighAI 9/10

GE HealthCare to acquire SOFIE Biosciences for $945 million, expanding U.S. PET supply footprint

GE HealthCare will acquire SOFIE Biosciences for $945 million in cash, expanding its U.S. PET radiopharmaceutical supply. The deal, expected to close in early 2027, will add SOFIE's 15 manufacturing sites and 21 cyclotrons to GE HealthCare's Pharmaceutical Diagnostics segment, enhancing its theranostics capabilities and access to high-growth areas. SOFIE's FAPI-74 radiopharmaceutical is in Phase III trials.

gmtoday.com2 min
OCT 7
$GEHCHighAI 9/10

GE HealthCare Agreed to Buy Trilantic-Backed SOFIE Biosciences for $945 Million:

GE HealthCare agreed to buy SOFIE Biosciences, a U.S. contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal, expected to close in early 2027, includes SOFIE's 15 U.S. manufacturing sites and rights to FAPI-74, an experimental PET imaging agent. SOFIE will continue serving existing customers post-acquisition. Trilantic North America, SOFIE's private equity backer, sold the company to GE HealthCare, which aims to expand its pharmaceutical diagnostics segment.

hedgeco.net2 min